Small molecule · Inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family · developed by Pfizer
Ritlecitinib is a kinase inhibitor that irreversibly binds the ATP site of JAK3 and TEC family kinases, inhibiting cytokine-induced STAT phosphorylation and immune receptor signaling. It is studied in severe alopecia areata.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 17, 2026). Read the full label for the exact wording, limitations and safety information.
Severe Alopecia Areata
Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →